Bio News
Workforce reduction is part of integration following acquisition to secure CAR-T therapy anito-cel About half of the 209 employees will be affected
Gilead will lay off 108 employees as part of the integration process following its $11 billion acquisition of Arcellx. The acquisition was aimed at securing anito-cel, a BCMA-targeted CAR-T therapy, and the workforce reduction will begin at the end of June. The U.S. Food and Drug Administration (FDA) is expected to decide by December 2026 whether to approve anito-cel as a fourth-line treatment for multiple myeloma.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
